Driehaus Capital Management LLC Has $19.07 Million Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Driehaus Capital Management LLC reduced its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 25.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 121,702 shares of the company's stock after selling 41,602 shares during the period. Driehaus Capital Management LLC owned 0.42% of Krystal Biotech worth $19,066,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. US Bancorp DE grew its position in shares of Krystal Biotech by 8.7% in the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after purchasing an additional 82 shares during the last quarter. Summit Investment Advisors Inc. grew its position in shares of Krystal Biotech by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company's stock valued at $407,000 after purchasing an additional 82 shares during the last quarter. Crossmark Global Holdings Inc. grew its position in shares of Krystal Biotech by 5.5% in the fourth quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company's stock valued at $362,000 after purchasing an additional 121 shares during the last quarter. Envestnet Asset Management Inc. grew its position in shares of Krystal Biotech by 1.1% in the fourth quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company's stock valued at $1,822,000 after purchasing an additional 121 shares during the last quarter. Finally, Perigon Wealth Management LLC grew its position in shares of Krystal Biotech by 1.5% in the fourth quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company's stock valued at $1,200,000 after purchasing an additional 123 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

Insider Activity at Krystal Biotech

In related news, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. This represents a 5.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. This represents a 1.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is owned by corporate insiders.

Krystal Biotech Stock Up 5.5%

Shares of KRYS traded up $7.25 during trading hours on Monday, reaching $139.43. The stock had a trading volume of 335,707 shares, compared to its average volume of 300,548. Krystal Biotech, Inc. has a 52 week low of $131.05 and a 52 week high of $219.34. The firm has a 50-day moving average of $171.56 and a 200 day moving average of $170.01. The company has a market cap of $4.03 billion, a P/E ratio of 46.63 and a beta of 0.79.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $88.18 million during the quarter, compared to the consensus estimate of $98.66 million. As a group, equities analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on KRYS. Jefferies Financial Group assumed coverage on Krystal Biotech in a research report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a report on Tuesday, May 6th. Chardan Capital reissued a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a report on Wednesday, May 7th. Cantor Fitzgerald reissued an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. Finally, Citigroup boosted their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $218.63.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).